The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

Authors
Rice, GPA Paszner, B Oger, J Lesaux, J Paty, D Ebers, G
Citation
Gpa. Rice et al., The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b, NEUROLOGY, 52(6), 1999, pp. 1277-1279
Citations number
10
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
NEUROLOGY
ISSN journal
00283878 → ACNP
Volume
52
Issue
6
Year of publication
1999
Pages
1277 - 1279
Database
ISI
SICI code
0028-3878(19990412)52:6<1277:TEONAI>2.0.ZU;2-E
Abstract
The fate of the neutralizing antibody (NAB) in MS patients treated with int erferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon beta-1b. NAB were measured with the myxovirus p rotein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.